Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Because combination therapy is required to treat human toxoplasmosis, we examined combinations of the ketolides HMR 3004 and HMR 3647 with atovaquone, clindamycin or sulphadiazine in a murine model of toxoplasmosis. An oral dose of 50 mg/kg/day of HMR 3004 protected 30% of mice lethally infected with Toxoplasma gondii. The same dose protected 100% of infected mice when administered in combination with non-protective doses of atovaquone, clindamycin or sulphadiazine. Similar results were noted with 25 mg/kg/day of HMR 3647. These results demonstrate that these drug combinations are highly effective for treating toxoplasmosis in mice.
Araujo
F G
FG
Research Institute, Palo Alto Medical Foundation, CA, USA.
Khan
A A
AA
Bryskier
A
A
Remington
J S
JS
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053626:Atovaquone; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D048628:Ketolides; D018942:Macrolides; D051379:Mice; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use; D013411:Sulfadiazine / Q000008:administration & dosage / Q000627:therapeutic use; D014122:Toxoplasma; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000981:Antiprotozoal Agents; D048628:Ketolides; D018942:Macrolides; D009285:Naphthoquinones; C105420:RU 64004; D013411:Sulfadiazine; D002981:Clindamycin; C106791:telithromycin; D053626:Atovaquone